{"id":748485,"date":"2023-04-18T08:04:30","date_gmt":"2023-04-18T12:04:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/"},"modified":"2023-04-18T08:04:30","modified_gmt":"2023-04-18T12:04:30","slug":"lineage-to-present-at-2023-aaps-national-biotechnology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/","title":{"rendered":"Lineage to Present at 2023 AAPS National Biotechnology Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Lineage to Present at 2023 AAPS National Biotechnology Conference<\/b><\/p>\n<p>CARLSBAD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=8e3d40aefbd8784ccabf8c53e4ce2ea2\">Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will present at the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Feventscribe.net%2F2023%2FNBC%2F&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=2023+American+Association+of+Pharmaceutical+Scientists+%28AAPS%29+National+Biotechnology+Conference&amp;index=2&amp;md5=3b28adb25ca3dc7f65528f7ccc97f114\">2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference<\/a>, on April 25<sup>th<\/sup>, 2023 at 10:00 am Eastern Time, as part of <i>\u201cThe <\/i><i>Evolution of Cellular Therapy Symposium,\u201d<\/i> moderated<i \/>by Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc. The \u201c<i>Advances in Therapeutic Development Across Modalities<\/i>\u201d panel, will also feature presenters from Intellia Therapeutics and Takeda Pharmaceutical Company Ltd., who will be discussing the rapid advancement of technologies and practices for monitoring exposure, immunophenotyping, and clinical endpoints around cellular modalities as well as considerations around allogeneic versus autologous cell therapies. The 2023 AAPS National Biotechnology Conference is taking place at the Philadelphia Marriott Downtown Hotel, April 23-26, 2023.<\/p>\n<p><b>About AAPS<\/b><\/p>\n<p>\nFounded in 1986, the American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 7,000 individual members and over 10,000 actively participating stakeholders employed in academia, industry, government, and other pharmaceutical science related research institutes worldwide. At AAPS, we strive to create a community that will further our mission: to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health. For additional information, please visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eventscribe.net%2F2023%2FNBC%2F&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.eventscribe.net%2F2023%2FNBC%2F&amp;index=3&amp;md5=d12f7b2f50e5142d94d54fb886916edf\">https:\/\/www.eventscribe.net\/2023\/NBC\/<\/a> or follow the conversation for the event on Twitter at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAAPSComms&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=%40AAPSComms&amp;index=4&amp;md5=5c84d96fbd7a7b952240aa59c198bbfe\">@AAPSComms<\/a>, using the hashtags # NBC2023 #AAPSNBC.<\/p>\n<p><b>About Lineage Cell Therapeutics, Inc.<\/b><\/p>\n<p>\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage\u2019s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage\u2019s clinical and preclinical programs are in markets with billion dollar opportunities and include five allogeneic (\u201coff-the-shelf\u201d) product candidates: (i) OpRegen<sup>\u00ae<\/sup>, a retinal pigment epithelial cell therapy in Phase 2a development for the treatment of geographic atrophy secondary to age-related macular degeneration, is being <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.lineagecell.com%2Fnews-releases%2Fnews-release-details%2Flineage-establishes-exclusive-worldwide-collaboration-genentech&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=developed&amp;index=5&amp;md5=e5f382182f2656cdb9ba27d2bb7661f0\">developed<\/a> under a worldwide collaboration with Roche and Genentech, a member of the Roche Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, a dendritic cell therapy produced from Lineage\u2019s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=www.lineagecell.com&amp;index=6&amp;md5=6de1bc43015821784b1f8fa8f56d4541\">www.lineagecell.com<\/a> or follow the company on Twitter <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FLineageCell&amp;esheet=53382450&amp;newsitemid=20230418005216&amp;lan=en-US&amp;anchor=%40LineageCell&amp;index=7&amp;md5=582107222d50b5138077ddc30efaaffd\">@LineageCell<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230418005216\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230418005216\/en\/<\/a><\/span><\/p>\n<p><b>Lineage Cell Therapeutics, Inc. IR<br \/>\n<\/b><br \/>Ioana C. Hone<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:ir@lineagecell.com\">ir@lineagecell.com<\/a>)<br \/>\n<br \/>(442) 287-8963<\/p>\n<p><b>LifeSci Advisors<br \/>\n<\/b><br \/>Daniel Ferry<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:daniel@lifesciadvisors.com\">daniel@lifesciadvisors.com<\/a>)<br \/>\n<br \/>(617) 430-7576<\/p>\n<p><b>Russo Partners \u2013 Media Relations<br \/>\n<\/b><br \/>Nic Johnson or David Schull<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:Nic.johnson@russopartnersllc.com\">Nic.johnson@russopartnersllc.com<\/a>)<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:David.schull@russopartnersllc.com\">David.schull@russopartnersllc.com<\/a>)<br \/>\n<br \/>(212) 845-4242<\/p>\n<p><b>KEYWORDS:<\/b> California Pennsylvania United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Science Stem Cells Biotechnology Research Pharmaceutical General Health Health Genetics<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230418005216\/en\/1765407\/3\/LINEAGE_2023_RGB_JPG_1740x360.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Lineage to Present at 2023 AAPS National Biotechnology Conference CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, on April 25th, 2023 at 10:00 am Eastern Time, as part of \u201cThe Evolution of Cellular Therapy Symposium,\u201d moderatedby Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc. The \u201cAdvances in Therapeutic Development Across Modalities\u201d panel, will also feature presenters from Intellia Therapeutics and Takeda Pharmaceutical Company Ltd., who will be discussing the rapid advancement of technologies and practices for monitoring exposure, immunophenotyping, and clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lineage to Present at 2023 AAPS National Biotechnology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748485","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lineage to Present at 2023 AAPS National Biotechnology Conference CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, on April 25th, 2023 at 10:00 am Eastern Time, as part of \u201cThe Evolution of Cellular Therapy Symposium,\u201d moderatedby Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc. The \u201cAdvances in Therapeutic Development Across Modalities\u201d panel, will also feature presenters from Intellia Therapeutics and Takeda Pharmaceutical Company Ltd., who will be discussing the rapid advancement of technologies and practices for monitoring exposure, immunophenotyping, and clinical &hellip; Continue reading &quot;Lineage to Present at 2023 AAPS National Biotechnology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-18T12:04:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lineage to Present at 2023 AAPS National Biotechnology Conference\",\"datePublished\":\"2023-04-18T12:04:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/\"},\"wordCount\":584,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/\",\"name\":\"Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-04-18T12:04:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lineage to Present at 2023 AAPS National Biotechnology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk","og_description":"Lineage to Present at 2023 AAPS National Biotechnology Conference CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage\u2019s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, on April 25th, 2023 at 10:00 am Eastern Time, as part of \u201cThe Evolution of Cellular Therapy Symposium,\u201d moderatedby Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc. The \u201cAdvances in Therapeutic Development Across Modalities\u201d panel, will also feature presenters from Intellia Therapeutics and Takeda Pharmaceutical Company Ltd., who will be discussing the rapid advancement of technologies and practices for monitoring exposure, immunophenotyping, and clinical &hellip; Continue reading \"Lineage to Present at 2023 AAPS National Biotechnology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-18T12:04:30+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lineage to Present at 2023 AAPS National Biotechnology Conference","datePublished":"2023-04-18T12:04:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/"},"wordCount":584,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/","name":"Lineage to Present at 2023 AAPS National Biotechnology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-04-18T12:04:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230418005216r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-to-present-at-2023-aaps-national-biotechnology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lineage to Present at 2023 AAPS National Biotechnology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748485"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748485\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}